SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca is conducting a $550M follow-on offering of 31.4M shares at…

Erasca, Inc. · 424B5 filed Jul 14, 2026 at 17:01 ET

At the news

MIXEDIMPACT 6/10

424B5 filed Jul 14, 2026 at 17:01 ET

Erasca is conducting a $550M follow-on offering of 31.4M shares at $17.50 (2.2% discount to last sale), with net proceeds of ~$516M to fund R&D for its RAS/MAPK pipeline. The filing also discloses encouraging updated Phase 1 data for lead candidate ERAS-0015, showing a 57% uORR8wk in 2L KRAS G12X PDAC at the 32mg RDE dose. The combination of dilutive financing and positive clinical data creates a mixed signal for the stock.

  • Offering of 31,428,572 shares at $17.50 per share, raising $550M in gross proceeds (~$516M net)
  • Underwriters have a 30-day option to purchase an additional 4,714,285 shares
  • Post-offering shares outstanding: 342,235,460 (or 346,949,745 if overallotment exercised)
  • New investors face immediate dilution of $14.84 per share (85% of offering price)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access